Health

Tenth Record-Breaking Year in a Row for ZEISS

STUTTGART, Germany, Dec. 11, 2019 /PRNewswire/ -- The ZEISS Group continued its growth trajectory, with revenue and earnings reaching new heights in fiscal year 2018/19, which ended30 September 2019. Revenue grew by 11 percent, reaching 6.428 billion euros (previous year: 5.817 billion euros). Adj...

2019-12-11 20:59 2343

GemVax announced phase II results of GV1001 for Alzheimer's disease treatment at CTAD 2019

SEOUL, South Korea, Dec. 11, 2019 /PRNewswire/ -- The 12th Clinical Trials on Alzheimer's Disease (CTAD) 2019 was held inSan Diego, USA, from December 4-7. At the CTAD, the results of various Alzheimer's disease clinical trials were shared, and it provided a glimpse into the possibility of treati...

2019-12-11 18:40 1373

Xinhua Silk Road: E. China Nanjing Jiangbei New Area aims to develop life and health industry

BEIJING, Dec. 11, 2019 /PRNewswire/ -- Nanjing Jiangbei New Area, a state-level new area in East China'sJiangsu Province, is committed to building a 100 billion-yuan level life and health industrial cluster and becoming a gene city inChina. The news was announced by Luo Qun, a member of the Stan...

2019-12-11 16:52 3312

West China Hospital to build new hospital in Chengdu Tianfu New Area

CHENGDU, China, Dec. 11, 2019 /PRNewswire/ -- West China Hospital of Sichuan University, a prestigious medical center located inChengdu, Sichuan province, signed an agreement on Dec. 5 with the Chengdu Management Committee of Tianfu New Area, China's 11th national-level development area, to build...

2019-12-11 13:47 3119

CStone announces enrollment target reached in the global Phase III VOYAGER trial of avapritinib in Chinese patients with third-line GIST

SUZHOU, China, Dec. 11, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) today announced that the on-going, global Phase III VOYAGER clinical trial of avapritinib, an investigational drug discovered by CStone's partner, Blueprint Medicines, has completed target ...

2019-12-11 11:00 2917

AGC Biologics Expands Plasmid DNA Offering

SEATTLE, Dec. 11, 2019 /PRNewswire/ -- AGC Biologics, a global Contract Development and Manufacturing Organization (CDMO) for Biopharmaceuticals, is significantly expanding its CDMO services with plasmid DNA (pDNA) offerings from itsHeidelberg site in Germany. With the demand for pDNA growing rap...

2019-12-11 09:06 2175

Kazia Initiates Preparatory Activities to Bring GDC-0084 into GBM AGILE, an International Phase II / III Study in Glioblastoma

SYDNEY, Dec. 11, 2019 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that it's lead program, GDC-0084, has been selected to join GBM AGILE, an international, academic-led, multi-drug adaptive phase ...

2019-12-11 08:41 6487

Ascentage Pharma Releases Updated Data of its Novel BCR-ABL Inhibitor, HQP1351, in an Oral Presentation Nominated for "Best of ASH"

SUZHOU, China and ROCKVILLE, Md., Dec. 11, 2019 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally-focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the updated results ...

2019-12-11 08:00 12323

Vision Impact Institute: New Reports on State of Vision Will Renew Global Focus on the Societal Impact of Poor Vision

First WHO World Health Report on Vision and Essilor Report on Eliminating Poor Vision underscore need to include vision health in global public health agenda DALLAS, Dec. 11, 2019 /PRNewswire/ -- The Vision Impact Institute welcomes the release of two new complementary and aligned reports on t...

2019-12-11 03:42 1721

Conversa Honored by Frost & Sullivan for its Clinically Intelligent Connectivity Platform that Improves Care, Enhances Patient and Provider Experience

Conversa has built a game-changing, real-time, "patient signals" model SANTA CLARA, Calif., Dec. 10, 2019 /PRNewswire/ -- Based on its recent analysis of the North American patient care management market, Frost & Sullivan recognizesConversa Health with the 2019 North American Visionary Innovation...

2019-12-10 22:00 904

PointClickCare Integrated Care Coordination Platform Applauded by Frost & Sullivan for Bridging the Communication Gap between Acute and Post-acute Healthcare Providers

Harmony by PointClickCare Enables Coordinated and Collaborative Care Delivery on a Secure and Integrated platform SANTA CLARA, California, Dec. 10, 2019 /PRNewswire/ -- Based on its recent analysis of the North American long-term and post-acute care (LTPAC) IT management market, Frost & Sullivan...

2019-12-10 22:00 1110

Breakthrough in Medical Electronics - A Novel Mixed & Augmented Reality Smart Glasses Surgical Navigation Solution

TAICHUNG, Dec. 10, 2019 /PRNewswire/ -- The mixed reality technology for surgery usually shown in the movies has now become a reality with the latest technological offering from theTaiwan-based company – Taiwan Main Orthopaedics Biotechnology and the branding name of medical devices is SURGLAS...

2019-12-10 16:34 922

Results of Fully-human BCMA CAR-T for the Treatment of Relapsed/Refractory Multiple Myeloma Co-developed by Innovent and IASO BIO Presented at the 2019 ASH Annual Meeting

SUZHOU, China, Dec. 10, 2019 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic and other major diseases, today announced that th...

2019-12-10 16:00 4135

CStone's anti-PD-L1 antibody demonstrates promising antitumor activity with a complete response rate of 33.3% and a good safety profile in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma

SUZHOU, China, Dec. 10, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) updated results from the CS1001-201 trial in a poster presentation at the 2019 American Society of Hematology (ASH) Annual Meeting. CS1001-201 trial is a single-arm, multicenter Phase II c...

2019-12-10 11:38 2677

Farrer Park Hospital Implements Non-Invasive Treatment for Prostate Cancer Patients in Singapore

SINGAPORE, Dec. 10, 2019 /PRNewswire/ -- Farrer Park Hospital is pleased to announce that it is the first inSouth East Asia to have implemented the Focal One® High-Intensity Frequency Ultrasound (HIFU) Robotic Technology, a non-invasive prostate cancer treatment, for patients with early-stage pro...

2019-12-10 08:15 3273

Townsville Hospital Treats First Australian Patient With Elekta Unity MR-Linac, a Transformative Approach to Precision Radiation Therapy

Ability to adapt daily treatment based on real-time MR imaging enables new approach to hard-to-treat cancers TOWNSVILLE, Australia, Dec. 10, 2019 /PRNewswire/ -- Elekta (EKTA-B.ST) today announced that Townsville Hospital inQueensland has treated the first patient in Australia using Elekta Unity ...

2019-12-10 08:13 6273

TechMah Medical & LimaCorporate Receive First 510k Approval for Smart SPACE Digital Technology

UDINE, Italy, Dec. 10, 2019 /PRNewswire/ -- LimaCorporate is pleased to announce the FDA510K approval for Smart SPACE Shoulder 3D Planner & 3D Positioner. Smart SPACE is an innovative digital platform developed by TechMah Medical thanks to collaboration with LimaCorporate, who entered into a mil...

2019-12-10 02:08 2289

Gracell Announces Progressive Outcomes from Multiple Human Clinical Trials to Investigate FasTCAR and Dual CAR Cell Platform Technologies

SUZHOU, China and SHANGHAI, Dec. 9, 2019 /PRNewswire/ -- Gracell Biotechnologies Co., Ltd ("Gracell"), a clinical-stage immune cell therapy company, today announced the progressive clinical outcomes for leading product candidates FasTCAR-19, Dual CAR-19-22, and Dual CAR-BCMA-19 at the American...

2019-12-09 22:00 1394

Publication of First In-Human Data Reveals Safety & Efficacy of Tigilanol Tiglate in Solid Tumours

* First in-human Clinical Phase I study of intratumoural tigilanol tiglate (EBC-46) has been published in The Lancet's EBioMedicine journal; * An efficacious dose was achieved and a Maximum Tolerated Dose (MTD) was not reached, indicating tigilanol tiglate tolerability in humans; * Promising...

2019-12-09 21:01 1454

BJ Bioscience Announces First Patient Dosed in FIH Trial of BJ-001 in Patients with Locally Advanced/Metastatic Solid Tumors

HANGZHOU, China, Dec. 9, 2019 /PRNewswire/ -- BJ Bioscience Inc. (the 'company') today announced that the first patient was successfully dosed on December 4, 2019 in the first-in-human (FIH) trial of the company's BJ-001 program at NEXT ONCOLOGY inSan Antonio, Texas.

2019-12-09 21:00 1556